Literature DB >> 20086085

Assessment of the duration of protection in Campylobacter jejuni experimental infection in humans.

David R Tribble1, Shahida Baqar, Daniel A Scott, Michael L Oplinger, Fernando Trespalacios, David Rollins, Richard I Walker, John D Clements, Steven Walz, Paul Gibbs, Edward F Burg, Anthony P Moran, Lisa Applebee, A Louis Bourgeois.   

Abstract

A human Campylobacter jejuni infection model provided controlled exposure to assess vaccine efficacy and investigate protective immunity for this important diarrheal pathogen. A well-characterized outbreak strain, C. jejuni 81-176, was investigated using a volunteer experimental infection model to evaluate the dose range and duration of protection. Healthy Campylobacter-seronegative adults received C. jejuni strain 81-176 via oral inoculation of 10(5), 10(7), or 10(9) CFU (5 adults/dose), which was followed by clinical and immunological monitoring. Based on dose range clinical outcomes, the 10(9)-CFU dose (n = 31) was used to assess homologous protection at 28 to 49 days (short-term veterans [STV]; n = 8) or 1 year (long-term veterans [LTV]; n = 7) after primary infection. An illness dose effect was observed for naïve subjects (with lower doses, 40 to 60% of the subjects were ill; with the 10(9)-CFU dose, 92% of the subjects were ill) along with complete protection for the STV group and attenuated illness for the LTV group (57%). Partial resistance to colonization was seen in STV (25% of the subjects were not infected; 3-log-lower maximum excretion level). Systemic and mucosal immune responses were robust in naïve subjects irrespective of the dose or the severity of illness. In contrast, in STV there was a lack of circulating antibody-secreting cells (ASC), reflecting the local mucosal effector responses. LTV exhibited comparable ASC responses to primary infection, and anamnestic fecal IgA responses likely contributed to self-resolving illness prior to antibiotic treatment. Campylobacter antigen-dependent production of gamma interferon by peripheral blood mononuclear cells was strongly associated with protection from illness, supporting the hypothesis that TH1 polarization has a primary role in acquired immunity to C. jejuni. This study revealed a C. jejuni dose-related increase in campylobacteriosis rates, evidence of complete short-term protection that waned with time, and immune response patterns associated with protection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20086085      PMCID: PMC2849408          DOI: 10.1128/IAI.01021-09

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  53 in total

1.  Persistent Campylobacter jejuni infections in patients infected with the human immunodeficiency virus (HIV).

Authors:  D M Perlman; N M Ampel; R B Schifman; D L Cohn; C M Patton; M L Aguirre; W L Wang; M J Blaser
Journal:  Ann Intern Med       Date:  1988-04       Impact factor: 25.391

Review 2.  Epidemiology of Campylobacter jejuni infections.

Authors:  M J Blaser; D N Taylor; R A Feldman
Journal:  Epidemiol Rev       Date:  1983       Impact factor: 6.222

3.  Comprehensive analysis of bacterial risk factors for the development of Guillain-Barre syndrome after Campylobacter jejuni enteritis.

Authors:  Michiaki Koga; Michel Gilbert; Masaki Takahashi; Jianjun Li; Saiko Koike; Koichi Hirata; Nobuhiro Yuki
Journal:  J Infect Dis       Date:  2006-01-19       Impact factor: 5.226

4.  Campylobacter Enteritis and the Guillain-Barré Syndrome.

Authors:  Irving Nachamkin
Journal:  Curr Infect Dis Rep       Date:  2001-04       Impact factor: 3.725

Review 5.  Host-pathogen interactions in Campylobacter infections: the host perspective.

Authors:  Riny Janssen; Karen A Krogfelt; Shaun A Cawthraw; Wilfrid van Pelt; Jaap A Wagenaar; Robert J Owen
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

6.  Clinical features of sporadic Campylobacter infections in Norway.

Authors:  G Kapperud; J Lassen; S M Ostroff; S Aasen
Journal:  Scand J Infect Dis       Date:  1992

7.  Serologic study of two clusters of infection due to Campylobacter jejuni.

Authors:  M J Blaser; D J Duncan; M T Osterholm; G R Istre; W L Wang
Journal:  J Infect Dis       Date:  1983-05       Impact factor: 5.226

Review 8.  Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome.

Authors:  Pieter A van Doorn; Liselotte Ruts; Bart C Jacobs
Journal:  Lancet Neurol       Date:  2008-10       Impact factor: 44.182

9.  In vivo phase variation and serologic response to lipooligosaccharide of Campylobacter jejuni in experimental human infection.

Authors:  Martina M Prendergast; David R Tribble; Shahida Baqar; Daniel A Scott; John A Ferris; Richard I Walker; Anthony P Moran
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

10.  Dendritic cells from C57BL/6 mice undergo activation and induce Th1-effector cell responses against Campylobacter jejuni.

Authors:  Vijay A K Rathinam; Kathleen A Hoag; Linda S Mansfield
Journal:  Microbes Infect       Date:  2008-08-05       Impact factor: 2.700

View more
  35 in total

Review 1.  Use of Pathogen-Specific Antibody Biomarkers to Estimate Waterborne Infections in Population-Based Settings.

Authors:  Natalie G Exum; Nora Pisanic; Douglas A Granger; Kellogg J Schwab; Barbara Detrick; Margaret Kosek; Andrey I Egorov; Shannon M Griffin; Christopher D Heaney
Journal:  Curr Environ Health Rep       Date:  2016-09

Review 2.  Global Epidemiology of Campylobacter Infection.

Authors:  Nadeem O Kaakoush; Natalia Castaño-Rodríguez; Hazel M Mitchell; Si Ming Man
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

Review 3.  A capsule conjugate vaccine approach to prevent diarrheal disease caused by Campylobacter jejuni.

Authors:  Alexander C Maue; Frédéric Poly; Patricia Guerry
Journal:  Hum Vaccin Immunother       Date:  2014-03-14       Impact factor: 3.452

4.  The host-pathogen interaction in Campylobacter jejuni infection of chickens: An understudied aspect that is crucial for effective control.

Authors:  Cosmin Chintoan-Uta
Journal:  Virulence       Date:  2016-09-26       Impact factor: 5.882

Review 5.  Immunology of gut mucosal vaccines.

Authors:  Marcela F Pasetti; Jakub K Simon; Marcelo B Sztein; Myron M Levine
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

6.  Campylobacter jejuni-mediated induction of CC and CXC chemokines and chemokine receptors in human dendritic cells.

Authors:  Lan Hu; Mechelle D Bray; Yansheng Geng; Dennis J Kopecko
Journal:  Infect Immun       Date:  2012-06-11       Impact factor: 3.441

7.  Identification of immunogenic and virulence-associated Campylobacter jejuni proteins.

Authors:  Lene N Nielsen; Thomas A Luijkx; Christina S Vegge; Christina Kofoed Johnsen; Piet Nuijten; Brendan W Wren; Hanne Ingmer; Karen A Krogfelt
Journal:  Clin Vaccine Immunol       Date:  2011-12-07

8.  Caught in the act: in vivo development of macrolide resistance to Campylobacter jejuni infection.

Authors:  J C Lindow; F Poly; D R Tribble; P Guerry; M P Carmolli; S Baqar; C K Porter; K K Pierce; M J Darsley; K S Sadigh; E A Dill; B D Kirkpatrick
Journal:  J Clin Microbiol       Date:  2010-06-16       Impact factor: 5.948

Review 9.  The Data Behind Risk Analysis of Campylobacter Jejuni and Campylobacter Coli Infections.

Authors:  Racem Ben Romdhane; Roswitha Merle
Journal:  Curr Top Microbiol Immunol       Date:  2021       Impact factor: 4.291

10.  Outcome of infection of C57BL/6 IL-10(-/-) mice with Campylobacter jejuni strains is correlated with genome content of open reading frames up- and down-regulated in vivo.

Authors:  J A Bell; J P Jerome; A E Plovanich-Jones; E J Smith; J R Gettings; H Y Kim; J R Landgraf; T Lefébure; J J Kopper; V A Rathinam; J L St Charles; B A Buffa; A P Brooks; S A Poe; K A Eaton; M J Stanhope; L S Mansfield
Journal:  Microb Pathog       Date:  2012-08-31       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.